UUUmmugul Uyeturk

Ummugul Uyeturk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ummugul Uyeturk has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of General Characteristics of Renal Cell Carcinoma Patients: A Single Center Experience

    by Ümmügül Üyetürk, Tuba Taslamacıoğlu Duman, Burak Yılmaz, Nadire Küçüköztaş, Uğur Üyetürk

  • Open Access

    Dermatofibrosarcoma Protuberans: A Rare Malignancy

    by Ümmügül Üyetürk, Tuba Taslamacioğlu Duman, Selma Erdoğan Düzcü, Nadire Küçüköztaş, Fahri Yilmaz

    Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor characterized by protuberant growth pattern of skin and subcutaneous tissue. The annual incidence is 4.2 per million. It is often seen between the ages of 20-50 years. This study aimed to evaluate the characteristics of patients with DFSP. METHODS Patients who visited our clinic were retrospectively evaluated. RESULTS All patients were females and the median age was 42 (29-60) years. The evaluated tumor sites were observed in the body/trunk in one patient, at the hip in two, and at the proximal lower extremity in two. Surgical excision was done in all of them as initial treatment. Re-excision was needed in three patients. One of the patients underwent punch biopsy for diagnosis and surgical removal of the tumor with a negative surgical margin. One of the patients underwent radiotherapy. The median follow-up time was 10 (6-26) months. During the median follow-up, there was no local recurrence or metastasis. CONCLUSION As initial treatment, it is important to surgically remove tumors that had no distant metastasis. Positive or near surgical margins should be resected again. If a negative surgical margin cannot be achieved, radiotherapy should be used as the treatment. Imatinib mesylate is used for treatment in unresectable, recurrent, and/or metastatic tumors.


    • 27 June 2014
      • Vol. 19  (2) , 365-71

    Treatment decision plans matter in elderly patients with gastrointestinal cancer: suboptimal or optimal?

    by Ummugul Uyeturk, Ibrahim Turker, Oznur Bal, Ayse Demirci, Ozlem Uysal Sonmez, Kaan Helvaci, Burcin Budakoglu, Ulku Yalcintas Arslan, Berna Oksuzoglu

    Aging is an important risk factor for cancer. Molecular changes and defective immunity associated with aging result in increased susceptibility to many carcinogens of the gastrointestinal system (GIS). Comorbidities and changes in drug metabolism in elderly patients make the treatment of GIS cancers difficult. Between January 2009 and December 2012, a total of 790 patients diagnosed with GIS cancers were retrospectively evaluated. Among them, 357 patients aged ≥ 65 years constituted the study population in which the patient characteristics, disease location, TNM stage, ECOG PS, co-morbidities, chemotherapy regimens and overall survival (OS) were assessed. The patient median age was 71 years (range 65-94). Cancer localizations were colorectal cancer (CRC), gastric cancer, and the pancreaticobiliary system (PBS) cancer in 178 (49.9%), 124 (34.7%), and 55 (15.4%) patients, respectively. A total of 260 (69%) patients underwent chemotherapy: 167 (64.3%) patients received optimal chemotherapy, and 93 (35.7%) suboptimal chemotherapy. The median OS was 47, 14, and 11 months in CRC, gastric, and PBS cancers, respectively. OS was better in the optimally-treated group than in the suboptimally-treated group among patients with all types of cancer. OS was 67 vs 19 months (p<0.001), 17 vs 8 months (p=0.004), and 12 vs 10 months (p=0.46) in CRC, gastric, and PBS cancers in the optimal and suboptimal chemotherapy groups, respectively. Multivariate analysis showed that the disease stage in all cancer types and optimal chemotherapy in the CRC group were important predictors of survival (p<0.001 and p=0.021, respectively). Cancer is usually in advanced stage at the time of diagnosis in these elderly patients and screening programs might improve outcomes in this age group. Patients with GIS cancers (especially CRC and gastric cancer) should be encouraged to receive optimal chemotherapy regimens.


  • Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology

    by Ummugul Uyeturk, Berna Oksuzoglu, Tulay Akman, Ibrahim Turker, Nur Sener, Didem Tastekin, Oznur Bal, Veli Berk, Ulku Yalcintas Arslan, Zuhat Urakci, et al.

    Primary metastatic breast cancer (PMBC) comprises 3–10 % of all BCs. PMBC is a heterogeneous disease. To date, little is known about the tumor characteristics, treatment results, and overall survival (OS) of patients with PMBC. Patients were considered to have PMBC if distant metastasis was evident within 3 months of the initial diagnosis of BC. Between September 2007 and April 2013, 466 PMBC patients were included in this study and analyzed retrospectively. The median age of the patients was 50 (18–90) years. Bone/soft tissue metastases were more frequent in the hormone receptor (HR)(+) human epidermal growth factor receptor (HER)2(−) group compared with the HR(−)HER2(−) and HR(−)HER2(+) groups (p < 0.001), whereas visceral organ metastasis was more frequent in the HR(−)HER2(−) and HR(−)HER2(+) groups (p < 0.001). The OS was affected by Eastern Cooperative Oncology Group performance status, tumor histology, receptor status, and the site of metastasis (p < 0.001, p < 0.001, p < 0.001, and p = 0.011, respectively). According to the first-line systemic treatment choices of the patients, the longest median OS was observed in the HR(+)HER2(+) group who received hormonotherapy combined with trastuzumab after chemotherapy (86 months, 95 % CI 23.8–148.1) and the shortest median OS was observed in the HR(−)HER2(−) group who received chemotherapy only (24 months, 95 % CI 17.9–30.0) (p < 0.001). Bisphosphonate therapy or radiotherapy had no significant effect on OS (p = 0.733, 0.603). In multivariate analysis, hormonotherapy, chemotherapy + trastuzumab, trastuzumab + hormonotherapy following chemotherapy, and surgery were the most important prognostic factors for OS, respectively (p < 0.001, p = 0.025, p = 0.027, p = 0.029). The general characteristics of the primary tumor are important for the prognosis and survival of patients with PMBC. Interestingly, patients who underwent primary breast tumor surgery, even those at the metastatic stage upon admission, had the longest survival.


  • Open Access

    Risk Factors for Stage IV Breast Cancer at the Time of Presentation in Turkey

    by Ummugul Uyeturk, Ali Murat Tatli, Sebahat Gucuk, Berna Oksuzoglu, Arife Ulas, Nilufer Avci, Mehmet Fatih Ozbay, Seyda Gunduz, Muhammed Bulent Akinci, Derya Kivrak Salim, et al.

    Breast cancer (BC) is the one of the most common cancers in women. It is also a leading cause of death. Unfortunately, some patients initially present with distant metastases and are diagnosed with stage IV disease that is nearly always, by then, incurable. This retrospective analysis investigated the risk factors for stage IV BC that may underlie such late presentation. In all, 916 patients with BC who visited the medical oncology polyclinic of eight different centres in Turkeybetween December 2011 and January 2013 were analysed. A total of 115 patients (12.6%) presented with stage IV disease. In univariate analysis; to comparing these with patients at other stages, no statistical difference was found for median diagnosis age or age at menarche (p=0.611 and p=0.820), whereas age at menopause and age at first live birth were significant (p=0.018 and p=0.003). No difference was detected in terms of accompanying diseases, use of oral contraceptives and hormone replacement therapy, smoking, alcohol consumption and the rate of family history of BC between the patients (p=0.655, p=0.389, p=0.762, p=0.813, p=0.229, p=0.737). However, screening methods were employed less often, the rate of illiteracy was higher, and the rate of other cancers was higher in patients with stage IV BC (p=0.022, p=0.022, p=0.018). No statistical difference was observed between the patients in terms of tumour histopathology, and status of oestrogen receptor, progesterone receptor, or human epidermal growth factor-2 receptor (p=0.389, p=0.326, p=0.949, p=0.326). Grade 3 tumours were more frequent in patients with stage IV disease (p<0.001). On multivariate analysis, risk factors for stage IV breast cancer at the time of presentation were found to be age at first live birth and educational level (p=0.003 and p=0.047). Efforts should be made to perform mammography scans, in particular, at regular intervals through national training programs for all women, particularly those with family histories of breast and other types of cancer, and to establish early diagnosis of BC long before it proceeds to stage IV. Additionally, women's education had better be upgraded. In order to make women aware of BC, national education-programmes must be organised.


  • Open Access

    Assessment of general characteristics of patients with primary metastatic breast carcinoma: single center experience

    by Ummugul Uyeturk, Burcin Budakoglu, İbrahim Turker, Kaan Helvaci, Ozlem Uysal Sonmez, Gulali Aktas, Ulku Yalcintas Arslan, Omur Berna Cakmak Oksuzoglu

    Introduction: Breast cancer (BC) is a heterogeneous disease. Several subgroups have been identified, according to the clinical presentation and radiographic, pathological, biological, and molecular characteristics of the tumor. Intrinsic genetic heterogeneity may be responsible for these...


  • Open Access

    Isolated ovarian metastasis of gastric cancer: Krukenberg tumor

    by Ummugul Uyeturk, Serife Hulya Arslan, Oznur Bal, Ulku Yalcintas Arslan, Omur Berna Cakmak Oksuzoglu

    Introduction: Gastric cancer, one of the most common cancers in the world, rarely metastasizes to the ovaries. Ovarian metastases of gastric signet ring cell cancer (SRCC) are referred to as Krukenberg tumors and account for 1–2% of all ovarian cancers. Here, we analyze the characteristics,...


  • Prognostic factors in gastrointestinal stromal tumors: multicenter experience of 333 cases from Turkey.

    by Mesut Seker, Alper Sevinc, Ramazan Yildiz, Sener Cihan, Mehmet Ali Kaplan, Ayse Gokdurnali, Faysal Dane, Emel Yaman, Halit Karaca, Dilsen Colak, et al.

    Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract. In an attempt to survey the approximate incidence, clinicopathological characteristics, and immunophenotypic features of GISTs in Turkey, we conducted a clinicopathological and immunohistochemical analysis of GISTs. Three hundred and thirty-three patients with GIST from nine institutions in Turkey were retrospectively evaluated. Between January 2001 and March 2011, a total of 333 patients with GISTs were included; of these, 204 (61.2%) were male and 129 (38.8%) were female. The median age was 55 years (range; 22-102 years). At the median follow-up of 26 months (range; 4-166 months), the 1-, 3- and 5-year OS rates of the 333 patients were 96.9%, 85.8% and 78.5%, respectively. The 5-year DFS rate was 40%. The 5-year OS rate and median OS time for the patients with R0 resection were significantly higher than for patients with metastatic diseases (79.7 vs. 75.7% and not reached vs. 115 months, respectively, p=0.04). Although our results should be confirmed by prospective studies, we believe that they contribute to the literature because the study included both resectable and metastatic or unresectable GIST patients and multicenter findings from Turkey.


  • Open Access

    Hyperkalemia in a Patient with Advanced Hepatocellular Carcinoma Probably Due to Sorafenib: Case Report

    by Ümmügül Üyetürk, Burçin Budakoğlu, Kaan Helvaci, Özlem Uysal Sönmez, İbrahim Türker, Ülkü Yalçintaş Arslan, Berna Öksüzoğlu, Nurullah Zengi̇n

    Sorafenib is an oral tyrosine kinase inhibitor used in the treatment of metastatic hepatocellular carcinoma (HCC). Its common adverse reactions include diarrhea, hand-foot syndrome, rash, cardiac ischemia or infarction, hypertension, elevated serum lipase and hypophosphatemia. A 35-year-old male patient with unresectable HCC was treated with sorafenib for progressive disease after locoregional chemoembolization. In the second month of the sorafenib treatment, he was admitted to the emergency department with weakness and drowsiness. His serum potassium level was 8.3 mmol/ L (3.5-5.5 mmol/L) which was accompanied with mild elevations in liver enzymes. Sorafenib treatment was stopped and emergency hemodialysis was applied. His potassium level reduced to normal levels and was stabilized.

  • Open Access

    Primary breast mucosa-associated lymphoid tissue (MALT) lymphoma transformation to diffuse large B-cell lymphoma: A case report

    by Serife Hulya Arslan, Ummugul Uyeturk, Emre Tekgunduz, Sultan Cigdem Irkkan, Meltem Kurt Yuksel, Itir Sirinoglu Demiriz, Fevzi Altuntaş

    Primary non-Hodgkin’s lymphoma (NHL) of the breast constitutes 0.04%-0.53% of all malignancies and 2.2% of extra nodal lymphomas. In total, 7%-8% of all B-cell lymphomas are the mucosa-associated lymphoid tissue (MALT) type, of which up to 50% of primary gastric MALT lymphoma. Herein we present a patient with breast MALT lymphoma that transformed to diffuse large B-cell lymphoma (DLBCL). A 69-year-old female presented with a mass on her left breast. Physical examination showed a 3 × 3-cm mass located 1 cm from the areola on the upper lateral quadrant of the breast at the 1 o’clock position, which was fixed and firm. Excisional biopsy was performed and pathologic examination of the specimen showed MALT lymphoma transformation to DLBCL. The patient was staged as II-EA. The rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) protocol was scheduled as treatment. Following 6 courses of R-CHOP, 2 additional courses of rituximab were administered. Positron emission tomography (PET)-CT was done at the end of the treatment. PET showed that the patient was in complete remission. At the time this report was written, the patient was being followed-up at the outpatient clinic on a regular basis. Lymphoma of the breast is a rarity among malignant tumors of the breast. The most common type of lymphoma is DLBCL. Breast MALT lymphoma is extremely rare. Primary MALT lymphoma of the breast can transform from low grade to high grade and recurrence is possible; therefore, such patients should be monitored carefully for transformation.u